Cardio3 BioSciences SA of Belgium said that its previously announced European initial public offering of shares has raised €23 million from investors in Belgium, France, the UK, the Netherlands, Scandinavia and the US.
Orexo AB of Sweden said that it has received US Food and Drug Administration approval for Zubsolv (buprenorphine/naloxone), a product to be used with counselling and psychosocial support to treat people suffering from opioid dependence.
Valneva, a company created from the merger of Intercell AG of Austria and Vivalis SA of France, has raised €40 million in a share placement in order to support future vaccine and antibody product development. The offer was oversubscribed.
A project to develop biomarker-guided personalised vaccines for patients with glioblastoma has received €6 million in European Union funding under the Framework 7 programme. Immatics Biotechnologies GmbH is the coordinator.
For several years now scientists have been using computer science and advanced chemistry to produce experimental protein therapeutics that they say incorporate the best features of the small molecule drug and the antibody therapeutic. Bicycle Therapeutics Ltd of the UK is an example of this approach with its technology for structurally modified peptides.
AstraZeneca Plc will invest up to $100 million over five years in its previously-announced collaboration the Karolinska Institutet in Sweden to create a new centre for research into cardiovascular and metabolic diseases.
Privately-held Immunocore Ltd of the UK has secured a licencing deal with Genentech (Roche) to discover and develop therapies against multiple of cancer targets. The deal is potentially valued at more than $320 million.
Ten new medicines including GlaxoSmithKline’s Tafinlar (dabrafenib) for metastatic melanoma, and Sanofi SA’s Lemtrada (alemtuzumab) for multiple sclerosis have been recommended for marketing by the European Medicines Agency.
A proposal to fundamentally change the way clinical trial data is handled is now open for public debate.
The European Medicines Agency’s main scientific committee, the CHMP, is recommending approval of the cellular immunotherapy for prostate cancer, Provenge (sipuleucel-T). Provenge was approved by the Food and Drug Administration in 2010.